Baby Boomers to Spark Huge Gains in Biotechnology – that is a fact.
Biotechnology stocks in the United States are off to a tremendous start in 2017, and it’s mostly because of one consumer segment: Baby Boomers.
As Baby Boomers step into their 50s and 60s, most of them are turning towards the biotech sector to not only live longer, but also to improve the quality of their lives.
Baby Boomers are skilled when it comes to managing their wealth, and the average Baby Boomer will have saved up $136,200 for retirement between the ages of 55 and 65. That isn’t enough at all.
Portfolio Wealth Global will be making sure you stay updated with innovative medical treatments that help keep aging at bay.
Baby Boomers are facilitating the economic development of the biotech field by investing in medical device and biotech firms, as well as through the consumption of different biotech products.
These companies rely on the money spent by Baby Boomers to make lifesaving discoveries. The demands made by Baby Boomers not only include treatments, but cures as well, and they have the potential to push the U.S. biotech industry to new highs.
In the coming years, therapies that deal with diabetes, obesity, cardiovascular disease, pain, and cancer will drive the growth of the biotech industry.
Baby Boomers are not getting any younger; at the same time, they are not ready to feel old quite yet, either.
According to the Boomers, aging is something akin to a disease, and this fuels their expenditures towards premium-quality products that drive high-margin biotech sales up.
Baby Boomers constitute a need-driven market segment for the global biotech industry. They are afflicted with chronic diseases and are willing to pay to safeguard their health and maintain their lifestyle.
This kind of consumer takes health into their own hands, and they possess the resources to search for highly-personalized medical solutions that will cure them.
They are responsible for the demand for specialized lifestyle treatments and cosmetic procedures.
In terms of the U.S. biotech industry, this is a growing, predictable niche market that shows no signs of fading. In fact, the more the population grows, the bigger this segment will become.
My research partner Tom Beck and I expect that aging Baby Boomers would demand customized, effective medicine that is compatible with their affluent lifestyles.
This kind of “macro” driver is especially significant for the United States, where biotech consumers wield a lot more power than they do in other nations. The best opportunity is in the U.S., as Boomers are a force to be reckoned with.
In the United States, the population continues to grow and age like it always has. These Baby Boomers have affected the biotechnology market unlike any other.
They take it upon themselves to drive the political and social agenda of the nation, and for that reason, they focus on remaining active and healthy at all times, even during their retirement period.
They are ready to invest huge amounts to get their hands on biotech solutions and medicine that extend and improve their lives.
Portfolio Wealth Global sees opportunities in marijuana legalization, and our latest stock suggestion was up 18% just hours after we profiled it, and this is only the beginning.
The future is in cutting-edge biotechnology.